|
|
The Pharmacy Quality Assurance Commission (commission) is aware of the multiple court rulings related to the FDA’s approval on mifepristone. At its May 4, 2023 business meeting, the commission stated that it is lawful to dispense and prescribe mifepristone in Washington and it would not take disciplinary action against its licensees, or find licensees deficient as part of an inspection, solely on the basis of prescribing, dispensing and delivering mifepristone pursuant to a valid prescription or collaborative drug therapy agreement (CDTA). Commission licensees should consider any obligations required under federal law including any requirements related to the REMS Program.
|
|
|
|
